The Europe Idiopathic Pulmonary Fibrosis Market would witness market growth of 6.1% CAGR during the forecast period (2021-2027).
Factors such as shifting lifestyle patterns, rising nicotine product usage, and growing health awareness among the general public about efficient IPF management measures are directly proportional to the growth of the overall industry. In addition to pharmacological treatments, IPF patients get a variety of non-pharmacological treatments. Lung transplants, mechanical ventilation, oxygen therapy, and pulmonary rehabilitation are the most common non-pharmacological treatments. In general, the treatment strategy for IPF is mostly determined by the patient's symptoms, illness stage, and overall health.
Incidence and death rates would rise, and the prevalence of the disease is projected to climb as the population ages. In addition, occupational and environmental exposures, gastric reflux, and hereditary factors are all potential risk factors. Moreover, progressive fibrosis with loss of normal lung tissue results in restricted gas exchange, decreased ventilation, respiratory discomfort and exercise limitation, poor quality of life, and eventually death.
In industrialized countries such as the United Kingdom, the elderly population is growing, and those over the age of 60 are more susceptible to lung diseases. In Western European countries, a large proportion of elderly persons are admitted to hospitals due to respiratory difficulties. In addition, to obtain important clinical proof for their treatments, market companies are forming partnerships with major organizations such as the National Institutes of Health.
According to the European Pulmonary Fibrosis Patient Charter, around 80,000 to 111,000 persons in Europe suffer from IPF, with 30,000 to 35,000 patients diagnosed each year. According to 2017 research by the National Centre for Biotechnology Information (NCBI), 54 percent of patients in Europe do not receive any antifibrotic medication. In 2019, 18.4 percent of EU citizens aged 15 and above reported smoking cigarettes on a daily basis. In fact, just 12.6 percent of EU citizens smoked less than 20 cigarettes per day, whereas 5.9 percent smoked 20 or more cigarettes per day. Such factors reveal the high susceptibility of the regional population towards lung-related diseases.
The Germany market dominated the Europe Idiopathic Pulmonary Fibrosis Market by Country 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $291.1 million by 2027. The UK market is experiencing a CAGR of 5.3% during (2021 - 2027). Additionally, The France market would exhibit a CAGR of 6.9% during (2021 - 2027).
Based on Drug Type, the market is segmented into Pirfenidone and Nintedanib. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Hospital Pharmacies, and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Idiopathic Pulmonary Fibrosis Market Size will Hit $4.7 Billion by 2027, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GNI Group Ltd., Shionogi & Co., Ltd., Mission Therapeutics Ltd., Galapagos NV, FibroGen, Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd., Bristol Myers Squibb Company, Boehringer Ingelheim International GmbH, and Biogen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
By Distribution Channel
- Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- GNI Group Ltd.
- Shionogi & Co., Ltd.
- Mission Therapeutics Ltd.
- Galapagos NV
- FibroGen, Inc.
- AstraZeneca PLC
- F. Hoffmann-La Roche Ltd.
- Bristol Myers Squibb Company
- Boehringer Ingelheim International GmbH
- Biogen, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Idiopathic Pulmonary Fibrosis Market, by Drug Type
1.4.2 Europe Idiopathic Pulmonary Fibrosis Market, by Distribution Channel
1.4.3 Europe Idiopathic Pulmonary Fibrosis Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Approvals and Trials
3.2.3 Acquisition and Mergers
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2017-2021)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
Chapter 4. Europe Idiopathic Pulmonary Fibrosis Market by Drug Type
4.1 Europe Pirfenidone Market by Country
4.2 Europe Nintedanib Market by Country
Chapter 5. Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel
5.1 Europe Retail Pharmacies Market by Country
5.2 Europe Hospital Pharmacies Market by Country
5.3 Europe Online Providers Market by Country
Chapter 6. Europe Idiopathic Pulmonary Fibrosis Market by Country
6.1 Germany Idiopathic Pulmonary Fibrosis Market
6.1.1 Germany Idiopathic Pulmonary Fibrosis Market by Drug Type
6.1.2 Germany Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.2 UK Idiopathic Pulmonary Fibrosis Market
6.2.1 UK Idiopathic Pulmonary Fibrosis Market by Drug Type
6.2.2 UK Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.3 France Idiopathic Pulmonary Fibrosis Market
6.3.1 France Idiopathic Pulmonary Fibrosis Market by Drug Type
6.3.2 France Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.4 Russia Idiopathic Pulmonary Fibrosis Market
6.4.1 Russia Idiopathic Pulmonary Fibrosis Market by Drug Type
6.4.2 Russia Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.5 Spain Idiopathic Pulmonary Fibrosis Market
6.5.1 Spain Idiopathic Pulmonary Fibrosis Market by Drug Type
6.5.2 Spain Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.6 Italy Idiopathic Pulmonary Fibrosis Market
6.6.1 Italy Idiopathic Pulmonary Fibrosis Market by Drug Type
6.6.2 Italy Idiopathic Pulmonary Fibrosis Market by Distribution Channel
6.7 Rest of Europe Idiopathic Pulmonary Fibrosis Market
6.7.1 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Drug Type
6.7.2 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 GNI Group Ltd.
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expenses
7.2 Shionogi & Co., Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Research & Development Expenses
7.3 Mission Therapeutics Ltd.
7.3.1 Company Overview
7.4 Galapagos NV
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional Analysis
7.4.4 Research & Development Expenses
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.5 FibroGen, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expenses
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Partnerships, Collaborations, and Agreements:
7.7 F. Hoffmann-La Roche Ltd.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Approvals and Trials:
7.7.5.2 Acquisitions and Mergers:
7.8 Bristol Myers Squibb Company
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Boehringer Ingelheim International Gmbh
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional & Segmental Analysis
7.9.4 Research & Development Expenses
7.9.5 Recent strategies and developments:
7.9.5.1 Partnerships, Collaborations, and Agreements:
7.9.5.2 Approvals and Trials:
7.10. Biogen, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Regional Analysis
7.10.4 Research & Development Expense
TABLE 1 Europe Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 2 Europe Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 3 Partnerships, Collaborations and Agreements – Idiopathic Pulmonary Fibrosis Market
TABLE 4 Approvals and Trials – Idiopathic Pulmonary Fibrosis Market
TABLE 5 Acquisition and Mergers – Idiopathic Pulmonary Fibrosis Market
TABLE 6 Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 7 Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 8 Europe Pirfenidone Market by Country, 2017 - 2020, USD Million
TABLE 9 Europe Pirfenidone Market by Country, 2021 - 2027, USD Million
TABLE 10 Europe Nintedanib Market by Country, 2017 - 2020, USD Million
TABLE 11 Europe Nintedanib Market by Country, 2021 - 2027, USD Million
TABLE 12 Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 13 Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 14 Europe Retail Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 15 Europe Retail Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 16 Europe Hospital Pharmacies Market by Country, 2017 - 2020, USD Million
TABLE 17 Europe Hospital Pharmacies Market by Country, 2021 - 2027, USD Million
TABLE 18 Europe Online Providers Market by Country, 2017 - 2020, USD Million
TABLE 19 Europe Online Providers Market by Country, 2021 - 2027, USD Million
TABLE 20 Europe Idiopathic Pulmonary Fibrosis Market by Country, 2017 - 2020, USD Million
TABLE 21 Europe Idiopathic Pulmonary Fibrosis Market by Country, 2021 - 2027, USD Million
TABLE 22 Germany Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 23 Germany Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 24 Germany Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 25 Germany Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 26 Germany Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 27 Germany Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 28 UK Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 29 UK Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 30 UK Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 31 UK Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 32 UK Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 33 UK Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 34 France Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 35 France Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 36 France Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 37 France Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 38 France Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 39 France Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 40 Russia Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 41 Russia Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 42 Russia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 43 Russia Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 44 Russia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 45 Russia Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 46 Spain Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 47 Spain Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 48 Spain Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 49 Spain Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 50 Spain Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 51 Spain Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 52 Italy Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 53 Italy Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 54 Italy Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 55 Italy Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 56 Italy Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 57 Italy Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 58 Rest of Europe Idiopathic Pulmonary Fibrosis Market, 2017 - 2020, USD Million
TABLE 59 Rest of Europe Idiopathic Pulmonary Fibrosis Market, 2021 - 2027, USD Million
TABLE 60 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2017 - 2020, USD Million
TABLE 61 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Drug Type, 2021 - 2027, USD Million
TABLE 62 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2017 - 2020, USD Million
TABLE 63 Rest of Europe Idiopathic Pulmonary Fibrosis Market by Distribution Channel, 2021 - 2027, USD Million
TABLE 64 Key Information – GNI Group Ltd.
TABLE 65 Key Information – Shionogi & Co., Ltd.
TABLE 66 Key Information – Mission Therapeutics Ltd.
TABLE 67 Key Information – Galapagos NV
TABLE 68 Key Information – FibroGen, Inc.
TABLE 69 Key Information – AstraZeneca PLC
TABLE 70 key information – F. Hoffmann-La Roche Ltd.
TABLE 71 Key Information – Bristol Myers Squibb Company
TABLE 72 Key Information – Boehringer Ingelheim International GmbH
TABLE 73 Key Information – Biogen, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2017-2021)
FIG 4 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2017, Apr – 2021, Dec) Leading Players
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.